#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #antibody drug conjugates

ADC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

ADC Therapeutics SA, a pioneering company in the field of antibody drug conjugates (ADCs) and traded on the NYSE under the symbol ADCT, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. This significant event is scheduled to take place in San Francisco, California, on January 15, 2026, at 10:30 AM PT. The presentation will be led by CEO Ameet Mallik, who will share insights into the company's latest innovations and therapeutic advancements.

The J.P. Morgan Healthcare Conference is one of the most anticipated events in the healthcare industry, bringing together leaders from various sectors to discuss the latest trends, challenges, and opportunities in healthcare and biotechnology. ADC Therapeutics’ participation underscores its commitment to leveraging innovative therapies that improve patient outcomes.

ADC Therapeutics is renowned for its focus on the development of targeted therapies, specifically antibody-drug conjugates. The company’s flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has recently gained attention due to its expedited approval by the FDA for treating relapsed or refractory diffuse large B-cell lymphoma. This treatment option not only demonstrates the efficacy of ADC technology but also embodies ADC Therapeutics’ commitment to transforming the future of cancer treatment.

During the conference, stakeholders can expect to learn about the current status of ADC Therapeutics' clinical programs, particularly the promising developments surrounding ZYNLONTA. The company has been actively pursuing research that combines ZYNLONTA with other therapeutic agents to enhance effectiveness in earlier lines of therapy. Furthermore, ABC Therapeutics is advancing its pipeline, which includes an innovative PSMA-targeting ADC, designed to utilize a next-generation payload coupled with a unique linker, aimed at targeting prostate cancer more effectively.

With a headquarters in Lausanne, Switzerland, ADC Therapeutics also operates in key markets such as London and New Jersey, emphasizing its global focus and reach. The company is dedicated to pushing the boundaries of ADC development, from clinical trials through to manufacturing and commercial distribution.

Interested parties can access a live webcast of the presentation through the Events and Presentations section on the ADC Therapeutics Investor Relations website. A replay will be available for approximately 30 days post-conference, allowing broader audience engagement with the company's strategic insights and future directions.

As ADC Therapeutics continues to drive innovation in the biopharma sector, its participation in prominent forums such as the J.P. Morgan Healthcare Conference is vital for fostering connections, sharing knowledge, and ultimately enhancing the therapeutic landscape for patients battling complex diseases. Stakeholders are encouraged to stay tuned for updates and key presentations that could influence future investments and partnerships within the biotech industry.

In preparing for the conference, it’s essential to highlight the challenges and opportunities ADC Therapeutics faces in its regulatory strategies, clinical trials, and international collaborations. Understanding these dynamics will be crucial for investors, healthcare providers, and other industry professionals following the company's journey.

In conclusion, the upcoming J.P. Morgan Healthcare Conference is not just an opportunity for ADC Therapeutics to showcase its achievements but also a platform for discussing the future trajectory of innovative therapies and their impact on patient care. As the event approaches, all eyes will be on ADC Therapeutics and its commitment to revolutionizing cancer treatment with groundbreaking ADC technology.